10000|10000|Public
5|$|Corzine {{spent some}} $200,000 {{of public funds}} on {{advertisements}} to promote {{a referendum on the}} 2007 New Jersey ballot to borrow $450million to fund <b>stem</b> <b>cell</b> research. The referendum faced strong opposition and was rejected despite the fact that $270million had previously been approved to build <b>stem</b> <b>cell</b> research centers.|$|E
5|$|Following her husband's death, Reagan {{remained}} {{active in}} politics, particularly relating to <b>stem</b> <b>cell</b> research. Beginning in 2004, she favored what many {{consider to be}} the Democratic Party's position, and urged President George W. Bush to support federally funded embryonic <b>stem</b> <b>cell</b> research, in the hope that this science could lead to a cure for Alzheimer's disease. Although she failed to change the president's position, she did support his campaign for a second term.|$|E
5|$|In 2005, Romney {{revealed}} {{a change of}} view regarding abortion, moving from the pro-choice positions expressed during his 1994 and 2002 campaigns to a pro-life one in opposition to Roe v. Wade. Romney attributed his conversion to an interaction with Harvard University biologist Douglas Melton, an expert on embryonic <b>stem</b> <b>cell</b> biology, although Melton vehemently disputed Romney's recollection of their conversation. Romney subsequently vetoed a bill on pro-life grounds that expanded access to emergency contraception in hospitals and pharmacies (the legislature overrode the veto). He also amended his position on embryonic <b>stem</b> <b>cell</b> research itself.|$|E
30|$|There {{are several}} types of <b>stem</b> <b>cells</b> under {{consideration}} for therapeutic purposes. Below we will introduce four kinds of <b>stem</b> <b>cells,</b> including embryonic <b>stem</b> <b>cells</b> (ES <b>cells),</b> induced pluripotent <b>stem</b> <b>cells</b> (iPSCs), neural <b>stem</b> <b>cells</b> (NSCs) and mesenchymal <b>stem</b> <b>cells</b> (MSCs).|$|R
5000|$|RI-SCBT, first, as the [...] "Department of Stem Cells" [...] was {{established}} in 2002 to advance researches on biology and technology of Embryonic <b>stem</b> <b>Cells,</b> Induced pluripotent <b>stem</b> <b>cells,</b> Germ line <b>Stem</b> <b>Cells,</b> Adult <b>Stem</b> <b>Cells,</b> Cancer <b>Stem</b> <b>Cells,</b> and Cord Blood <b>Stem</b> <b>Cells.</b>|$|R
25|$|Some <b>stem</b> <b>cells</b> form tumors after transplantation; pluripotency {{is linked}} to tumor {{formation}} especially in embryonic <b>stem</b> <b>cells,</b> fetal proper <b>stem</b> <b>cells,</b> induced pluripotent <b>stem</b> <b>cells.</b> Fetal proper <b>stem</b> <b>cells</b> form tumors despite multipotency.|$|R
5|$|For {{people who}} are not {{eligible}} for a <b>stem</b> <b>cell</b> transplant, immunotherapy with a combination of histamine dihydrochloride (Ceplene) and interleukin 2 (Proleukin) after the completion of consolidation has been shown to reduce the absolute relapse risk by 14%, translating to a 50% increase in the likelihood of maintained remission.|$|E
5|$|High-risk {{neuroblastoma}} {{is treated}} with intensive chemotherapy, surgery, radiation therapy, bone marrow / hematopoietic <b>stem</b> <b>cell</b> transplantation, biological-based therapy with 13-cis-retinoic acid (isotretinoin or Accutane) and antibody therapy usually administered with the cytokines GM-CSF and IL-2.|$|E
5|$|In 1998, Wilder {{collaborated on}} the book Gilda's Disease with {{oncologist}} Steven Piver, sharing personal experiences of Radner's struggle with ovarian cancer. Wilder himself was hospitalized with non-Hodgkin lymphoma in 1999, but confirmed in March 2005 that the cancer was in complete remission following chemotherapy and a <b>stem</b> <b>cell</b> transplant.|$|E
40|$|<b>Stem</b> <b>cells</b> are {{cells that}} can {{differentiate}} into more specialized cells. Of {{the two types}} of <b>stem</b> <b>cells,</b> embryonic <b>stem</b> <b>cells</b> and adult <b>stem</b> <b>cells,</b> embryonic <b>stem</b> <b>cells</b> are believed to be more pluripotent, meaning they are able to differentiate into more types of <b>cells</b> than adult <b>stem</b> <b>cells.</b> Due to this characteristic, embryonic <b>stem</b> <b>cells</b> are believed to have the potential to treat...|$|R
50|$|Chorionic villi are a {{rich source}} of <b>stem</b> <b>cells.</b> Biocell Center, a biotech company managed by Giuseppe Simoni, is {{studying}} and testing these types of <b>stem</b> <b>cells.</b> Chorionic <b>stem</b> <b>cells,</b> like amniotic <b>stem</b> <b>cells,</b> are uncontroversial multipotent <b>stem</b> <b>cells.</b>|$|R
30|$|Perinatal <b>stem</b> <b>cells</b> can be classed into 3 {{groups based}} on their origin; amniotic fluid <b>stem</b> <b>cells,</b> placental <b>stem</b> <b>cells</b> and {{umbilical}} cord <b>stem</b> <b>cells.</b>|$|R
5|$|McGovern has {{a pro-choice}} record on abortion. He {{voted against the}} Partial-Birth Abortion Ban Act in October 2003 and the Unborn Victims of Violence Act in February 2004. He {{supports}} <b>stem</b> <b>cell</b> research, having {{voted in favor of}} the <b>Stem</b> <b>Cell</b> Research Enhancement Act in 2005, 2007, and 2009. He voted for the Employment Non-Discrimination Act of 2007, which would have prevented employment {{discrimination on the basis of}} sexual orientation. He voted against the Federal Marriage Amendment, which would have constitutionally outlawed same-sex marriage, in 2004 and 2006, and co-sponsored the Respect for Marriage Act of 2009, which would allow the federal government to recognize same-sex marriages.|$|E
5|$|Mosaicism in horses {{is thought}} to account for some {{spontaneous}} occurrences of white, near-white, spotted, and roan horses. Mosaicism refers to mutations that occur after the single-cell stage, and therefore affect {{only a portion of}} the adult cells. Mosaicism may be one possible cause for the rare occurrence of brindle coloring in horses. Mosaic-white horses would be visually indistinguishable from dominant whites. Mosaicism could produce white or partially white foals if a <b>stem</b> <b>cell</b> in the developing foal underwent a mutation, or change to the DNA, that resulted in unpigmented skin and hair. The cells that descend from the affected <b>stem</b> <b>cell</b> will exhibit the mutation, {{while the rest of the}} cells are unaffected.|$|E
5|$|The {{discovery}} of insulin at the University of Toronto in 1921 is {{considered among the}} most significant events {{in the history of}} medicine. The <b>stem</b> <b>cell</b> was discovered at the university in 1963, forming the basis for bone marrow transplantation and all subsequent research on adult and embryonic stem cells. This was the first of many findings at Toronto relating to stem cells, including the identification of pancreatic and retinal stem cells. The cancer <b>stem</b> <b>cell</b> was first identified in 1997 by Toronto researchers, who have since found <b>stem</b> <b>cell</b> associations in leukemia, brain tumors and colorectal cancer. Medical inventions developed at Toronto include the glycaemic index, the infant cereal Pablum, the use of protective hypothermia in open heart surgery and the first artificial cardiac pacemaker. The first successful single-lung transplant was performed at Toronto in 1981, followed by the first nerve transplant in 1988, and the first double-lung transplant in 1989. Researchers identified the maturation promoting factor that regulates cell division, and discovered the T cell receptor, which triggers responses of the immune system. The university is credited with isolating the genes that cause Fanconi anemia, cystic fibrosis and early-onset Alzheimer's disease, among numerous other diseases. Between 1914 and 1972, the university operated the Connaught Medical Research Laboratories, now part of the pharmaceutical corporation Sanofi-Aventis. Among the research conducted at the laboratory was the development of gel electrophoresis.|$|E
40|$|Noncoding RNAs are {{critical}} regulatory factors in essentially {{all forms of}} life. <b>Stem</b> <b>cells</b> occupy a special position in cell biology and Biomedicine, and emerging results show that multiple ncRNAs play essential roles in <b>stem</b> <b>cells.</b> We discuss some of the known ncRNAs in <b>stem</b> <b>cells</b> such as embryonic <b>stem</b> <b>cells,</b> induced pluripotent <b>stem</b> <b>cells,</b> mesenchymal <b>stem</b> <b>cells,</b> adult <b>stem</b> <b>cells,</b> and cancer <b>stem</b> <b>cells</b> {{with a focus on}} long ncRNAs. Roles and functional mechanisms of these lncRNAs are summarized, and insights into current and future studies are presented...|$|R
40|$|Bone marrow {{microenvironment}} contains cellular and acellular compartments. The cellular compartment includes hematopoietic <b>stem</b> <b>cells,</b> mesenchymal <b>stem</b> <b>cells</b> {{and some}} other stromal cell types, while the acellular compartment is composed of scaffold proteins known as the extra cellular matrix. Direct cell-cell contact as well as cytokines secreted by mesenchymal <b>stem</b> <b>cells</b> during coculture of hematopoietic <b>stem</b> <b>cells</b> and mesenchymal <b>stem</b> <b>cells</b> {{play a critical role}} in hematopoiesis, and determines the fate of hematopoietic <b>stem</b> <b>cells.</b> Several studies have demonstrated the impact of mesenchymal <b>stem</b> <b>cells</b> on self-renewal, expansion, proliferation and differentiation of hematopoietic <b>stem</b> <b>cells</b> in vitro, which have shown different and contradictory results. In this paper, we will investigate the effect of mesenchymal <b>stem</b> <b>cells</b> on differentiation of hematopoietic <b>stem</b> <b>cells</b> in vitro...|$|R
40|$|Dental tissues {{provide an}} {{alternate}} source of <b>stem</b> <b>cells</b> compared with bone marrow {{and have a}} similar potency as that of bone marrow derived mesenchymal <b>stem</b> <b>cells.</b> It has been established there are six types of dental stem cells: Dental pulp <b>stem</b> <b>cells,</b> <b>stem</b> <b>cells</b> from human exfoliated deciduous teeth, <b>stem</b> <b>cells</b> from apical papilla, periodontal ligament <b>stem</b> <b>cells,</b> dental follicle progenitor <b>cells,</b> oral periosteum <b>stem</b> <b>cells</b> and recently gingival connective tissue <b>stem</b> <b>cells.</b> Most of the dental tissues have a common developmental pathway; thus, it is relevant to understand whether <b>stem</b> <b>cells</b> derived from these closely related tissues are programmed differently. The present review analyzes whether <b>stem</b> <b>cells</b> form dental tissues depict distinct characteristics by gaining insight into differences in their immunophenotype. In addition, to explore the possibility of establishing a unique phenotypic fingerprint of these <b>stem</b> <b>cells</b> by identifying the unique markers {{that can be used}} to isolate these <b>stem</b> <b>cells.</b> This, in future will help in developing better techniques and markers for identification and utilization of these <b>stem</b> <b>cells</b> for regenerative therapy...|$|R
5|$|The {{specific}} type of postremission therapy is individualized based on a person's prognostic factors (see above) and general health. For good-prognosis leukemias (i.e. inv(16), t(8;21), and t(15;17)), people will typically undergo an additional three to five courses of intensive chemotherapy, known as consolidation chemotherapy. For people {{at high risk of}} relapse (e.g. those with high-risk cytogenetics, underlying MDS, or therapy-related AML), allogeneic <b>stem</b> <b>cell</b> transplantation is usually recommended if the person is able to tolerate a transplant and has a suitable donor. The best postremission therapy for intermediate-risk AML (normal cytogenetics or cytogenetic changes not falling into good-risk or high-risk groups) is less clear and depends on the specific situation, including the age and overall health of the person, the person's values, and whether a suitable <b>stem</b> <b>cell</b> donor is available.|$|E
5|$|There {{is little}} {{prospect}} of significant new PD treatments {{in the near}} future. Currently active research directions include the search for new animal models {{of the disease and}} studies of the potential usefulness of gene therapy, <b>stem</b> <b>cell</b> transplants and neuroprotective agents.|$|E
5|$|Chemotherapy agents used in {{combination}} {{have been found}} to be effective against neuroblastoma. Agents commonly used in induction and for <b>stem</b> <b>cell</b> transplant conditioning are platinum compounds (cisplatin, carboplatin), alkylating agents (cyclophosphamide, ifosfamide, melphalan), topoisomerase II inhibitor (etoposide), anthracycline antibiotics (doxorubicin) and vinca alkaloids (vincristine). Some newer regimens include topoisomerase I inhibitors (topotecan and irinotecan) in induction which {{have been found to}} be effective against recurrent disease.|$|E
40|$|Recently, {{a variety}} of mesenchymal <b>stem</b> <b>cells</b> (MSCs), {{including}} dental pulp <b>stem</b> <b>cells,</b> <b>stem</b> <b>cells</b> from human exfoliated deciduous teeth, <b>stem</b> <b>cells</b> from apical papilla, periodontal ligament <b>stem</b> <b>cells,</b> and mesenchymal <b>stem</b> <b>cells</b> derived from human gingival, were isolated from orofacial and dental tissues. However, it is unknown whether these orofacial <b>stem</b> <b>cells</b> are derived from mesoderm or neural crest cell. In order to encourage orofacial MSC investigation, we provide detailed protocols for assessing lineage Â­differentiation of orofacial MSCs. Kentaro Akiyama, Chider Chen, Stan Gronthos, Songtao Sh...|$|R
40|$|<b>Stem</b> <b>cells</b> {{provide an}} {{attractive}} novel therapeutic approach for repair and replacement of pathologically damaged tissues. Adult <b>stem</b> <b>cells</b> are becoming largely recognised as {{potential source of}} <b>stem</b> <b>cells</b> for future therapy given the controversy around embryonic <b>stem</b> <b>cells.</b> Dental tissues are readily available source of adult <b>stem</b> <b>cells</b> following teeth extraction. Within teeth <b>Stem</b> <b>cells</b> reside in the dental pulp, the periodontal ligament and the apical papilla. These <b>cells</b> are multipotent <b>stem</b> <b>cells</b> of mesenchymal origin that can be successfully differentiated into various specialised cells. Using explants culture and magentic beads separation methods we isolated <b>stem</b> <b>cells</b> form dental pulp and periodontal ligament. We developed a protocol for in-vitro differentiation of dental pulp <b>stem</b> <b>cells</b> into functional neurons and odontobalsts. The osteogenic potential of periodontal ligament <b>stem</b> <b>cells</b> is also explored {{in addition to the}} effect of inflammation on renewal and regenerative capacity of these cells. We are particularly interested in the factors that determine fate and terminal differentiation of <b>stem</b> <b>cells</b> to help develop mechanisms for directed differentiation of <b>stem</b> <b>cells</b> for future tissue engineering and regenerative medicine...|$|R
40|$|To date, {{the oral}} cavity has yielded a diverse menagerie of adult <b>stem</b> <b>cells</b> that {{includes}} dental pulp <b>stem</b> <b>cells</b> (DPSCs), dental follicle <b>stem</b> <b>cells</b> (DFSCs), <b>stem</b> <b>cells</b> from apical papilla (SCAP), <b>stem</b> <b>cells</b> from human exfoliated deciduous teeth (SHED), periodontal ligament <b>stem</b> <b>cells</b> (PDLSCs), and gingival mesenchymal <b>stem</b> <b>cells</b> (GMSCs). These <b>stem</b> <b>cells</b> have various useful applications in clinical dentistry that is dental pulp regeneration after root canal treatment, osseous integration of titanium implants, and maxillofacial and periodontal regeneration. Stem cells-based approaches in clinical dentistry are reviewed by D. Hughes and B. Song, {{as well as}} S. Miran et al. within this special issue [...] ...|$|R
5|$|Crocodilians are polyphyodonts {{and able}} to replace each of their {{approximately}} 80 teeth up to 50 times in their 35 to 75-year lifespan. They are the only non-mammalian vertebrates with tooth sockets. Next to each full-grown tooth {{there is a small}} replacement tooth and an odontogenic <b>stem</b> <b>cell</b> in the dental lamina in standby, which can be activated when required. Tooth replacement slows significantly and eventually stops as the animal grows old.|$|E
5|$|For {{people with}} relapsed AML, the only proven {{potentially}} curative therapy is a hematopoietic <b>stem</b> <b>cell</b> transplant, {{if one has}} not already been performed. In 2000, the monoclonal antibody-linked cytotoxic agent gemtuzumab ozogamicin (Mylotarg) was approved in the United States for people aged more than 60 years with relapsed AML who are not candidates for high-dose chemotherapy. This drug was voluntarily withdrawn from the market by its manufacturer, Pfizer in 2010.|$|E
5|$|On July 14, 2009, House Democratic leaders {{introduced}} a 1,017-page plan for overhauling the U.S. health care system, which Obama wanted Congress to approve {{by the end}} of 2009. After much public debate during the Congressional summer recess of 2009, Obama delivered a speech to a joint session of Congress on September 9 where he addressed concerns over the proposals. In March 2009, Obama lifted a ban on using federal funds for <b>stem</b> <b>cell</b> research.|$|E
5000|$|<b>Stem</b> <b>cells</b> are {{cells that}} can {{differentiate}} to become {{different types of}} cells. [...] The hope is that <b>stem</b> <b>cells</b> transplanted into an injured area of the spinal cord will allow neuroregeneration. Types of cells being researched for use in SCI include embryonic <b>stem</b> <b>cells,</b> neural <b>stem</b> <b>cells,</b> mesenchymal <b>stem</b> <b>cells,</b> olfactory ensheathing cells, Schwann cells, activated macrophages, and induced pluripotent <b>stem</b> <b>cells.</b> When <b>stem</b> <b>cells</b> are injected {{in the area of}} damage in the spinal cord, they secrete neurotrophic factors, and these factors help neurons and blood vessels to grow, thus helping repair the damage. It is also necessary to recreate an environment in which <b>stem</b> <b>cells</b> will grow.|$|R
40|$|AbstractStem cells, such as {{embryonic}} <b>stem</b> <b>cells,</b> hematopoietic <b>stem</b> <b>cells,</b> neural <b>stem</b> <b>cells,</b> mesenchymal <b>stem</b> <b>cells,</b> {{and very}} small embryonic-like <b>stem</b> <b>cells,</b> are undifferentiated {{cells that are}} endowed with a high potential for proliferation and the capacity for self-renewal with retention of pluri/multipotency to differentiate into their progenies. Recently, studies regarding the biological functions of glycolipids and cell surface microdomains (caveolae, lipid rafts, or glycolipid-enriched microdomains) in <b>stem</b> <b>cells</b> are emerging. In this review, we introduce the expression patterns of glycolipids and the functional roles of cell surface microdomains in <b>stem</b> <b>cells...</b>|$|R
40|$|<b>Stem</b> <b>cells</b> can {{be derived}} from the embryo (embryonic <b>stem</b> <b>cells,</b> ESCs), from adult tissues (adult <b>stem</b> <b>cells,</b> ASCs), and by {{induction}} of fibroblasts (induced pluripotent <b>stem</b> <b>cells,</b> iPSs). Ethical problems, immunological rejection, and difficulties in obtaining human tissues limit the use of ESCs in clinical medicine. Induced pluripotent <b>stem</b> <b>cells</b> are difficult to maintain in vitro and carry a greater risk of tumor formation. Furthermore, the complexity of maintenance and propagation is especially difficult in the clinic. Adult <b>stem</b> <b>cells</b> can be isolated from several adult tissues and present the possibility of self-transplantation for the clinical treatment of a variety of human diseases. Recently, several ASCs have been successfully isolated and cultured in vitro, including hematopoietic <b>stem</b> <b>cells</b> (HSCs), mesenchymal <b>stem</b> <b>cells</b> (MSCs), epidermis <b>stem</b> <b>cells,</b> neural <b>stem</b> <b>cells</b> (NSCs), adipose-derived <b>stem</b> <b>cells</b> (ADSCs), islet <b>stem</b> <b>cells,</b> and germ line <b>stem</b> <b>cells.</b> Human mesenchymal <b>stem</b> <b>cells</b> originate mainly from bone marrow, cord blood, and placenta, but epidermis-derived MSCs have not yet been isolated. We isolated small spindle-shaped cells with strong proliferative potential during the culture of human epidermis cells and designed a medium to isolate and propagate these cells. They resembled MSCs morphologically and demonstrated pluripotency in vivo; thus, we defined these cells as human epidermis-derived mesenchymal <b>stem</b> cell-like pluripotent <b>cells</b> (hEMSCPCs). These hEMSCPCs present a possible new cell resource for tissue engineering and regenerative medicine...|$|R
5|$|<b>Stem</b> <b>cell</b> {{therapy is}} the {{replacement}} of damaged neurons by transplantation of stem cells into affected regions of the brain. Experiments have yielded mixed results using this technique in animal models and preliminary human clinical trials. Whatever their future therapeutic potential, stem cells are already a valuable tool for studying Huntington's disease in the laboratory.|$|E
5|$|The primary aims {{of therapy}} are {{returning}} function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications {{used in the}} management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many people, despite {{the fact that there is}} little supporting, comparable, replicated scientific study. <b>Stem</b> <b>cell</b> therapy is being studied.|$|E
5|$|Treatment and {{outcomes}} {{depends on the}} risk group a person is in. Treatments may include observation, surgery, radiation, chemotherapy, or <b>stem</b> <b>cell</b> transplantation. Low-risk disease in babies typically has a good outcome with surgery or simply observation. In high-risk disease chances of long term survival, however, are less than 40% despite aggressive treatment.|$|E
40|$|The {{three major}} sources of <b>stem</b> <b>cells</b> are {{embryonic}} <b>stem</b> <b>cells</b> (ESCs), fetal <b>stem</b> <b>cells</b> (FSCs), and adult (somatic) <b>stem</b> <b>cells.</b> <b>Stem</b> <b>cells</b> can be effective in the {{diagnosis and treatment of}} a wide spectrum of diseases. The FSCs from extra-embryonic tissues have the advantage of having fewer ethical concerns. We aimed to summarize the potential advantages and dis-advantages of these extra-embryonic fetal sources of <b>stem</b> <b>cells,</b> the collection methods, and clinical application fields...|$|R
40|$|Abstract Emerging {{evidence}} suggests that cancer <b>stem</b> <b>cells</b> account for the initiation and progression of cancer. While many types of cancer <b>stem</b> <b>cells</b> with specific markers have been isolated and identified, a variety of differences among them began to be appreciated. Cancer <b>stem</b> <b>cells</b> are hierarchical populations that consist of precancerous <b>stem</b> <b>cells,</b> primary cancer <b>stem</b> <b>cells,</b> migrating cancer <b>stem</b> <b>cells</b> and chemoradioresistant cancer <b>stem</b> <b>cells,</b> playing different roles in cancer initiation and progression. Here we propose a new concept "horizontal hierarchy of cancer stem cells" to distinguish them from vertical hierarchy cancer <b>stem</b> <b>cells,</b> cancer transient-amplifying cells and cancer differentiated cells, and summarize our current understanding of these subsets of cancer <b>stem</b> <b>cells</b> with the aim to open up novel therapeutic strategies for cancer based on this understanding. </p...|$|R
25|$|Thy-1 can be {{considered}} as a surrogate marker for various kind of <b>stem</b> <b>cells</b> (e.g. hematopoietic <b>stem</b> <b>cells</b> or HSCs). It is one of the popular combinatorial surface markers for FACS for <b>stem</b> <b>cells</b> in combination with other markers like CD34. In humans, Thy-1 is expressed on neurons and HSCs among others. It is considered a major marker of HSC pluripotency in concordance with CD34. In human HSCs, Thy1 cells are all CD34 positive. Thy 1 is also a marker of other kind of <b>stem</b> <b>cells,</b> for example: mesenchymal <b>stem</b> <b>cells,</b> hepatic <b>stem</b> <b>cells</b> ("oval cells"), keratinocyte <b>stem</b> <b>cells,</b> putative endometrial progenitor/(?)stem cells.|$|R
